RxDoctor Payments Data

Steven Rudolph, MD

Vascular Neurology · Brooklyn, NYNPI 1659437473

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (39.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Bayer at 39.4% of the total. Reporting peaked in 2020 at $1,105 and has fallen 87.1% since, to $143 in 2025.

$2,673in general payments, 2019–2025

Across 19 payments — averaging $140.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$1K
  • Abbott$950
  • Penumbra, Inc.$179
  • Genentech USA, Inc.$165
  • Smith+Nephew$143
  • Johnson & Johnson$105
  • plus $78 from 1 others

What the payments were for

  • Consulting fees$95036%
  • Travel & lodging$66325%
  • Food & beverage$1,06040%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer7$1,053
Abbott1$950
Penumbra, Inc.2$179
Genentech USA, Inc.4$165
Smith+Nephew1$143
Johnson & Johnson1$105
Stryker3$78

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,673 in reported general payments places this provider in the 75th percentile of 74 vascular neurology providers in New York.

See all vascular neurology providers in New York

Medicare billing

Part B allowed, 2024
$90,638
Medicare patients
342
Services billed
815

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban43$39,709
BrilintaTicagrelor12$7,348
Lacosamide11$1,408
Atorvastatin Calcium80$1,051
Memantine Hcl33$582
Levetiracetam15$395
Minocycline Hcl23$353
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide14$306
Metoprolol Succinate14$279
Rosuvastatin Calcium23$262
Hydrochlorothiazide27$252
Valsartan17$238
Duloxetine Hcl22$225
Pantoprazole Sodium12$156
ClopidogrelClopidogrel Bisulfate20$145

Paid to pharmacies, not to this prescriber.

Other vascular neurology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →